Differences in the course of hepatocellular carcinoma depending on the DAA treatment
DOI:
https://doi.org/10.56782/pps.236Keywords:
hepatocellular carcinoma, HCV, direct-acting antivirals, liver cirrhosis, liver tumorAbstract
Background and aims: 58 million people live with chronic hepatitis C virus (HCV) infection which can lead to liver cirrhosis and hepatocellular carcinoma (HCC). Currently, a non-interferon therapy based on direct-acting antivirals (DAA) is the standard treatment of HCV infection. This study aimed to assess the occurrence of HCC after treatment with DAA and evaluate whether the course of the disease and liver function is different in patients treated with DAA compared to those who did not receive such therapy.
Materials and methods: We studied the population of adult patients from the 2015-2021 period and analyzed the demographic and clinical data, including alcohol abuse, liver enzymes, Child-Pugh and model for end-stage liver disease scores, imaging tests, liver biopsy and elastography, if performed. The Mann-Whitney U and the McNemar’s tests were used. The p-value was set at 0.05.
Results: The study included n=34 patients with HCC. In this group n=22 patients (61%) were diagnosed with a chronic HCV infection and n=11 (50%) were receiving DAA treatment. Patients who were receiving DAA developed multiple HCC significantly less often compared to patients not treated with DAA (45.5% vs. 69.6%). We also observed a significantly less common occurrence of portal vein thrombosis (8.7% vs. 18.2%) and distant metastases (0.0% vs. 13.0%) in patients with HCC receiving DAA. Patients with HCC who underwent DAA therapy had significantly lower levels of serum liver enzymes in comparison with patients diagnosed with HCC and not receiving DAA.
Conclusions: HCC occurring in patients treated with DAA was more often associated with lymphadenopathy, multiple tumors, portal vein thrombosis and distant metastases probably due to restricted treatment qualification criteria. DAA treatment led to a decrease in the inflammatory activity in the liver. It is important to adjust qualification protocols so that all patients suffering from chronic HCV infection could receive the treatment as soon as possible.
Downloads
References
Hepatitis C. Available online: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c (accessed on 09.03.2024)
Freiman, J.M.; Wang, J.; Easterbrook, P.J.; et al. Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: Analysis of a global dataset. J. Hepatol. 2019, 71(1), 62-70. DOI:10.1016/j.jhep.2019.02.011 DOI: https://doi.org/10.1016/j.jhep.2019.02.011
Moosavy, S.H.; Davoodian, P.; Nazarnezhad, M.A.; et al. Epidemiology, transmission, diagnosis, and outcome of Hepatitis C virus infection. Electron. Physician 2017, 9(10), 5646. DOI:10.19082/5646 DOI: https://doi.org/10.19082/5646
safo-Agyei, K.O.; Samant, H. Hepatocellular Carcinoma. In StatPearls [Internet]. StatPearls Publishing. Published online June 12, 2023. Available online: https://www.ncbi.nlm.nih.gov/books/NBK559177/ (accessed on 09.03.2024).
Reddy, K.R.; McLerran, D.; Marsh, T.; et al. Incidence and Risk Factors for Hepatocellular Carcinoma in Cirrhosis: The Multicenter Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study. Gastroenterology 2023, 165(4), 1053-1063.e6. DOI:10.1053/J.GASTRO.2023.06.027 DOI: https://doi.org/10.1053/j.gastro.2023.06.027
Ahmed, O.A.; Elsebaey, M.A.; Fouad, M.H.A.; et al. Outcomes of Treatment and Predictors of Response to Sofosbuvir Plus Simeprevir in Hepatitis C Virus with Genotype-4 Infection. Infect. Disord. Drug Targets 2020, 20(3), 389-395. DOI:10.2174/1871526519666181218104600 DOI: https://doi.org/10.2174/22123989OTUyrODYjTcVY
Wang, M.; Zhang, Y.; Li, Z.; et al. Hepatitis C virus (HCV) genotype 2a has a better virologic response to antiviral therapy than HCV genotype 1b. Int. J. Clin. Exp. Med. 2015, 8(5), 7446-7456.
Liu, T.; Sha, K.; Yang, L.; et al. IL-28B Polymorphisms Correlated with Treatment Response in HCV-4 Mono-Infected Patients: A Meta-Analysis. PLoS One 2014, 9(3), Art. No: e98312. DOI:10.1371/JOURNAL.PONE.0091316 DOI: https://doi.org/10.1371/journal.pone.0091316
Daniel, K.E.; Saeian, K.; Rizvi, S. Real-world experiences with direct-acting antiviral agents for chronic hepatitis C treatment. J. Viral Hepat. 2020, 27(2), 195-204. DOI:10.1111/JVH.13218 DOI: https://doi.org/10.1111/jvh.13218
Asselah, T.; Marcellin, P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int. 2012, 32 Suppl. 1, 88-102. DOI:10.1111/J.1478-3231.2011.02699.X DOI: https://doi.org/10.1111/j.1478-3231.2011.02699.x
Ghany, M.G.; Nelson, D.R.; Strader, D.B.; et al. An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54(4), 1433-1444. DOI:10.1002/HEP.24641 DOI: https://doi.org/10.1002/hep.24641
Flisiak, R.; Urbánek, P.; Rokusz, L.; et al. New therapeutic options for HCV in Central Europe. Clin. Exp. Hepatol. 2016, 2(1), 7-11. DOI:10.5114/CEH.2016.58850 DOI: https://doi.org/10.5114/ceh.2016.58850
Kozbial, K.; Moser, S.; Schwarzer, R.; et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. J. Hepatol. 2016, 65(4), 856-858. DOI:10.1016/J.JHEP.2016.06.009 DOI: https://doi.org/10.1016/j.jhep.2016.06.009
Ioannou, G.N. HCC surveillance after SVR in patients with F3/F4 fibrosis. J. Hepatol. 2021, 74(2), 458-465. DOI:10.1016/J.JHEP.2020.10.016 DOI: https://doi.org/10.1016/j.jhep.2020.10.016
Kolly, P.; Waidmann, O.; Vermehren, J.; et al. Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study. J. Hepatol. 2017, 67(4), 876-878. DOI:10.1016/J.JHEP.2017.07.007 DOI: https://doi.org/10.1016/j.jhep.2017.07.007
Cardoso, H.; Vale, A.M.; Rodrigues, S.; et al. High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis. J. Hepatol. 2016, 65(5), 1070-1071. DOI:10.1016/J.JHEP.2016.07.027 DOI: https://doi.org/10.1016/j.jhep.2016.07.027
Kanda, T.; Lau, G.K.K.; Wei, L.; et al. APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. Hepatol. Int. 2019, 13(6), 649-661. DOI:10.1007/S12072-019-09988-7 DOI: https://doi.org/10.1007/s12072-019-09988-7
Sepanlou, S.G.; Safiri, S.; Bisignano, C.; et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 2020, 5(3), 245-266. DOI:10.1016/S2468-1253(19)30349-8 DOI: https://doi.org/10.1016/S2468-1253(19)30349-8
Flisiak, R.; Halota, W.; Tomasiewicz, K.; et al. Forecasting the disease burden of chronic hepatitis C virus in Poland. Eur. J. Gastroenterol. Hepatol. 2015, 27(1), 70-76. DOI:10.1097/MEG.0000000000000237 DOI: https://doi.org/10.1097/MEG.0000000000000237
Lawitz, E.; Sulkowski, M.S.; Ghalib, R.; et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014, 384(9956), 1756-1765. DOI:10.1016/S0140-6736(14)61036-9 DOI: https://doi.org/10.1016/S0140-6736(14)61036-9
Easterbrook, P.; Luhmann, N.; Newman, M.; et al. New WHO guidance for country validation of viral hepatitis B and C elimination. Lancet Gastroenterol. Hepatol. 2021, 6(10), 778-780. DOI:10.1016/S2468-1253(21)00267-3 DOI: https://doi.org/10.1016/S2468-1253(21)00267-3
Reig, M.; Mariño, Z.; Perelló; C.; et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J. Hepatol. 2016, 65(4), 719-726. DOI:10.1016/J.JHEP.2016.04.008 DOI: https://doi.org/10.1016/j.jhep.2016.04.008
Conti, F.; Buonfiglioli; F.; Scuteri, A.; et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J. Hepatol. 2016, 65(4), 727-733. DOI:10.1016/J.JHEP.2016.06.015 DOI: https://doi.org/10.1016/j.jhep.2016.06.015
Frazzoni, L.; Sikandar, U.; Metelli, F.; et al. Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis. J. Clin. Med. 2021, 10(8), Art. No: 1694. DOI:10.3390/JCM10081694 DOI: https://doi.org/10.3390/jcm10081694
Waziry, R.; Hajarizadeh, B.; Grebely, J.; et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J. Hepatol. 2017, 67(6), 1204-1212. DOI:10.1016/J.JHEP.2017.07.025 DOI: https://doi.org/10.1016/j.jhep.2017.07.025
Cento, V.; Nguyen, T.H.T.; Di Carlo, D.; et al. Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. PLoS One 2017, 12(5), Art. No: e0177352. DOI:10.1371/JOURNAL.PONE.0177352 DOI: https://doi.org/10.1371/journal.pone.0177352
Liu, Y.C.; Jeng, W.J.; Cheng, Y.T.; et al. Incidence and predictors for abnormal liver function during direct-acting antiviral agents in chronic hepatitis C patients. Medicine 2020, 99(37), Art. No e21898. DOI:10.1097/MD.0000000000021898 DOI: https://doi.org/10.1097/MD.0000000000021898
Asselah, T.; Kowdley, K.V.; Zadeikis, N.; et al. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Clin. Gastroenterol. Hepatol. 2018, 16(3), 417-426. DOI:10.1016/J.CGH.2017.09.027 DOI: https://doi.org/10.1016/j.cgh.2017.09.027
Puoti, M.; Foster, G.R.; Wang, S.; et al. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis. J. Hepatol. 2018, 69(2), 293-300. DOI:10.1016/J.JHEP.2018.03.007 DOI: https://doi.org/10.1016/j.jhep.2018.03.007
Orzechowska, D.; Klimowicz, K.; Stȩpień, A.; et al. Change in γ-glutamyl transpeptidase activity as a useful tool in identifying a group of patients with elevated risk of hepatocellular carcinoma development after DAA treatment of chronic hepatitis C. Clin. Exp. Hepatol. 2021, 7(1), 93-100. DOI:10.5114/CEH.2021.104466 DOI: https://doi.org/10.5114/ceh.2021.104466
Abdelaziz, A.O.; Nabil, M.M.; Abdelmaksoud, A.H.; et al. Tumor behavior of hepatocellular carcinoma after hepatitis C treatment by direct-acting antivirals: comparative analysis with non-direct-acting antivirals-treated patients. Eur. J. Gastroenterol. Hepatol. 2019, 31(1), 75-79. DOI:10.1097/MEG.0000000000001264 DOI: https://doi.org/10.1097/MEG.0000000000001264
El Fayoumie, M.; Abdelhady, M.; Gawish, A.; et al. Changing Patterns of Hepatocellular Carcinoma after Treatment with Direct Antiviral Agents. Gastrointest. Tumors 2020, 7(1-2), 50-60. DOI:10.1159/000505326 DOI: https://doi.org/10.1159/000505326
Fouad, M.; El Kassas, M.; Ahmed, E.; El Sheemy, R. Tumor characteristics of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C: Comparative analysis with antiviral therapy-naive patients. World J. Hepatol. 2021, 13(11), 1743-1752. DOI:10.4254/WJH.V13.I11.1743 DOI: https://doi.org/10.4254/wjh.v13.i11.1743
Fatima, T.; Mumtaz, H.; Khan, M.H.; et al. Patterns of Hepatocellular Carcinoma After Direct Antiviral Agents and Pegylated-Interferon Therapy. Cureus 2020, 12(11), Art. No: e11565. DOI:10.7759/CUREUS.11565 DOI: https://doi.org/10.7759/cureus.11565
Rekomendacja nr 24/2015 z dnia 30 marca 2015 r. Prezesa Agencji Oceny Technologii Medycznych i Taryfikacji w sprawie objęcia refundacją produktu leczniczego Olysio, symeprevir, kapsułki twarde 150 mg, 7 kapsułek, stosowanego w ramach programu lekowego: “Leczenie przewlekłego wirusowego zapalenia wątroby typu C, ICD-10 B. 18.2.” Available online: https://bipold.aotm.gov.pl/assets/files/zlecenia_mz/2015/012/REK/RP_24_2015_Olysio.pdf (accessed on 09.03.2024)
Opracowanie dotyczące oceny zasadności wprowadzenia zmian w zapisach programu lekowego: B.71 „Leczenie przewlekłego wirusowego zapalenia wątroby typu C terapią bezinterferonową (ICD-10 B18.2)”. Available online: https://bipold.aotm.gov.pl/assets/files/zlecenia_mz/2019/302/RPT/302_OT.4320.34.2019_zmiany_WZW_C_BIP.pdf (accessed on 09.03.2024)
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Agnieszka Lembas, Andrzej Załęski, Tomasz Mikuła, Joanna Jabłońska, Szymon Barczak, Barbara Badura, Alicja Wiercińska-Drapało
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
